SEC 13F Intelligence

Managers / Q2 2022 · view latest →

M28 Capital Management LP

CIK 0001807489 · 700 CANAL STREET, 1ST FLOOR, STAMFORD, CT, 06902 · 203-516-3730

Reported Value
$89M
Q2 2022
Positions
13
Filings on Record
18
2019–present window
Filed
Aug 12, 2022
original filing

Summary

M28 Capital Management LP reported $89M in U.S.-listed holdings across 13 positions for Q2 2022.

The portfolio is heavily concentrated: Wave Life Sciences alone accounts for 30.2% of reported value.

The book was largely unchanged from Q1 2022.

Portfolio Metrics

Turnover
+15.4%
vs prior filed quarter
Top-10 Concentration
+96.5%
share of reported value
Largest Position
+30.2%
Wave Life Sciences

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’21: $128MQ4 ’21Q1 ’22: $109MQ2 ’22: $89MQ3 ’22: $96MQ3 ’22Q4 ’22: $105MQ1 ’23: $88MQ2 ’23: $76MQ2 ’23Q3 ’23: $87MQ4 ’23: $121MQ1 ’24: $135MQ1 ’24Q2 ’24: $77MQ3 ’24: $91MQ4 ’24: $102MQ4 ’24Q1 ’25: $73MQ2 ’25: $59MQ3 ’25: $68MQ3 ’25Q4 ’25: $138MQ1 ’26: $54Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 61.2%Other: 38.8%
  • Common Stock · 61.2% · $55M
  • Other · 38.8% · $35M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
WAVE LIFE SCIENCES LTDADDED+2.43M8.28M+$15M$27M
ATRAGBXATARA BIOTHERAPEUTICS INCTRIMMED−120.1K269.3K−$2M$2M
TGTXTG THERAPEUTICS INCTRIMMED−321.7K726.2K−$7M$3M
MRTXEURMIRATI THERAPEUTICS INCTRIMMED−21.7K61.2K−$3M$4M
IVVDADAGIO THERAPEUTICS INCHELD+06.40M−$8M$21M
CURIS INCHELD+04.24M−$6M$4M
STOKSTOKE THERAPEUTICS INCHELD+0527.1K−$4M$7M
LEAP THERAPEUTICS INCHELD+02.66M−$2M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2022

13 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1WAVE LIFE SCIENCES LTDSHS30.17%$27M8.28M
2IVVDADAGIO THERAPEUTICS INChistory →COM23.53%$21M6.40M
3RCKTROCKET PHARMACEUTICALS INChistory →COM11.04%$10M715.9K
4STOKSTOKE THERAPEUTICS INChistory →COM7.81%$7M527.1K
5BBIOBRIDGEBIO PHARMA INChistory →COM4.75%$4M466.2K
6CURIS INCCOM NEW4.68%$4M4.24M
7MRTXEURMIRATI THERAPEUTICS INChistory →COM4.61%$4M61.2K
8TGTXTG THERAPEUTICS INChistory →COM3.46%$3M726.2K
9LEAP THERAPEUTICS INCCOM3.43%$3M2.66M
10VERVE THERAPEUTICS INCCOM3.06%$3M178.5K
11ATRAGBXATARA BIOTHERAPEUTICS INChistory →COM2.35%$2M269.3K
12PROQR THERAPEUTICS N VSHS EURO0.87%$779,0001.00M
13NEXI1EURNEXIMMUNE INCCOM0.24%$215,000133.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$54M9May 14, 202613F-HRchanges · EDGAR ↗
Q4 2025$138M9Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$68M9Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$59M9Aug 13, 202513F-HRchanges · EDGAR ↗
Q1 2025$73M11May 14, 202513F-HRchanges · EDGAR ↗
Q4 2024$102M11Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$91M11Nov 12, 202413F-HRchanges · EDGAR ↗
Q2 2024$77M11Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$135M11May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$121M10Feb 12, 202413F-HRchanges · EDGAR ↗
Q3 2023$87M11Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$76M12Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$88M14May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$105M14Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$96M12Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$89M13Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$109M13May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$128M12Feb 11, 202213F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.